AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cellectis Reports Share Capital and Voting Rights as of July 31, 2025
ByAinvest
Friday, Aug 8, 2025 6:09 am ET1min read
Cellectis (CLLS) reported 100,325,229 shares in its capital structure as of July 31, 2025, with 89,428,630 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth. The company specializes in gene-editing platforms for life-saving cell and gene therapies, with a focus on allogeneic CAR T immunotherapies in oncology. Headquartered in Paris, France, Cellectis is listed on Euronext Growth and the Nasdaq Global Market under the ticker CLLS.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet